An open-label, phase 2, single centre, randomised, crossover design bioequivalence study of AndroForte (R) 5 Compared With Testogel (R) 1% in Hypogonadal Men.
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2016
At a glance
- Drugs Testosterone (Primary) ; Testosterone
- Indications Hypogonadism
- Focus Pharmacokinetics
- Sponsors Lawley Pharmaceuticals
- 11 Sep 2012 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
- 06 Dec 2011 Status changed from not yet recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
- 25 Jul 2011 New trial record